Co-infection with 'superbug' spikes Covid virus replication 15-folds

Researchers have identified a protein found in superbugs that enhances SARS-CoV-2 replication by 10- to 15-fold

covid, corona, coronavirus
Photo: Bloomberg (Representative Image)
IANS Toronto
2 min read Last Updated : Mar 21 2023 | 5:55 PM IST

Researchers have identified a protein found in superbugs that enhances SARS-CoV-2 replication by 10- to 15-fold.

Global data shows nearly 10 per cent of severe Covid-19 cases involve a secondary bacterial co-infection -- with Staphylococcus aureus, also known as staph A, being the most common organism responsible for co-existing infections with SARS-CoV-2.

The study, published in the journal iScience, revealed that the addition of a "superbug" -- methicillin-resistant Staphylococcus aureus (MRSA) -- into the mix could make the Covid-19 outcome even more deadly.

While the mystery of how and why the combination of these two pathogens contributes to the severity of the disease remained unsolved, the researchers identified a protein -- IsdA -- found in all strains of staph A which boosts SARS-CoV-2 replication by 10- to 15-fold.

The findings of this study are significant and could help inform the development of new therapeutic approaches for Covid-19 patients with bacterial co-infections.

Interestingly, the study also showed that SARS-CoV-2 did not affect the bacteria's growth. This was contrary to what the researchers had initially expected.

"We started with an assumption that SARS-CoV-2 and hospitalisation due to Covid-19 possibly caused patients to be more susceptible to bacterial infections which eventually resulted in worse outcomes," said Mariya Goncheva, Professor of biochemistry and microbiology at the University of Victoria.

Goncheva said bacterial infections are most commonly acquired in hospital settings and hospitalisation increases the risk of co-infection.

"Bacterial infections are one of the most significant complications of respiratory viral infections such as Covid-19 and Influenza A. Despite the use of antibiotics, 25 per cent of patients co-infected with SARS-CoV-2 and bacteria, die as a result. This is especially true for patients who are hospitalised, and even more so for those in intensive care units. We were interested in finding why this happens," said Goncheva, who conducted the study while at University of Western Ontario.

--IANS

rvt/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Corona RemediesCoronavirus TestsCoronavirus Vaccine

First Published: Mar 21 2023 | 5:55 PM IST

Next Story